Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-01-14

FDA Approved: GIMOTI — Supplemental Application (Evoke Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for GIMOTI (metoclopramide hydrochloride) submitted by Evoke Pharma, resulting in labeling changes for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GIMOTI (metoclopramide hydrochloride)

Snippet

SUPPL AP for GIMOTI (METOCLOPRAMIDE HYDROCHLORIDE)